Recurrent Visceral Leishmaniasis in HIV Co-Infection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitute of Tropical Medicine, Belgium
About this trial
The aim is (1) to better understand the underlying causes and predispositions for relapse and parasite persistence in visceral leishmaniasis (VL) patients living with HIV and (2) to improve treatment monitoring of this target group in Ethiopia
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
VL-HIV infection 1.1. VL: microscopically confirmed parasite presence in spleen or bone marrow tissue at first episode or relapse; for known active chronic cases: decision to treat VL 1.2. HIV: confirmed viral infection (new or past)
≥18 years
Disqualifiers
Not willing to provide written informed consent
Not willing to adhere to the follow-up visits
Mentally or physically incapable to participate in the study (to the discretion of the treating physician)
Trial population
All HIV co-infected patients prospectively diagnosed with VL (either first infection or relapse) and known HIV co-infected patients recruited in previous studies
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
key host and pathogen factors of active chronicity in VL/HIV patients
Descriptive analysis of key host and pathogen factors that contribute to active chronicity in VL/HIV patients in northern Ethiopia
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Institute of Tropical Medicine, Belgium
Lead sponsor
Armauer Hansen Research Institute, Ethiopia
Collaborator
University of Gondar
Collaborator
Source ClinicalTrials.gov